...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Examination of the follicular lymphoma international prognostic index (FLIPI) in the national lymphocare study (NLCS): A prospective US patient cohort treated predominantly in community practices
【24h】

Examination of the follicular lymphoma international prognostic index (FLIPI) in the national lymphocare study (NLCS): A prospective US patient cohort treated predominantly in community practices

机译：在国家淋巴护理研究（NLCS）中检查滤泡性淋巴瘤国际预后指数（FLIPI）：在社区实践中主要接受治疗的前瞻性美国患者队列

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Because follicular lymphoma (FL) patients have heterogeneous outcomes, the FL international prognostic index (FLIPI) was developed to risk-stratify patients and to predict survival. However, limited data exist regarding the role of FLIPI in the era of routine first-line rituximab (R) and R-chemotherapy regimens and in the setting of community oncology practices. Patients and Methods: We evaluated the outcome data from the National LymphoCare Study (NLCS), a prospective, observational cohort study, which collects data on patients with FL in the United States (US) community practices. Results: Among 1068 male and 1124 female patients with FLIPI data, most were treated in US community practices (79%); 35% were FLIPI good risk, 30% intermediate risk, and 35% poor risk. FLIPI risk groups were significant predictors of overall survival (OS) and progression-free survival (PFS) for patients who undergo watchful waiting (WW), and those who receive non-R-containing regimens, R-alone, and R-chemotherapy combinations. Conclusions: In the setting of contemporary practice with routine R use, stratifying patients into good, intermediate, and poor FLIPI risk groups predicts distinct outcomes in terms of OS and PFS. FLIPI remains an important prognostic index in the R era and should be used in clinical practices to support discussions about prognosis.
机译：背景：由于滤泡性淋巴瘤（FL）患者的预后不同，因此制定了FL国际预后指数（FLIPI）可以对患者进行风险分层并预测存活率。但是，关于FLIPI在常规一线利妥昔单抗（R）和R化疗方案时代以及社区肿瘤学实践中的作用的数据有限。患者和方法：我们评估了一项全国性的前瞻性观察性队列研究国家淋巴瘤研究（NLCS）的结局数据，该研究收集了美国（US）社区实践中FL患者的数据。结果：在有FLIPI数据的1068例男性和1124例女性患者中，大多数接受了美国社区实践的治疗（79％）; 35％是FLIPI良好风险，30％是中等风险，35％是不良风险。 FLIPI风险组是观察等待（WW）以及接受非R方案，R单独治疗和R化疗联合治疗的患者的总体生存（OS）和无进展生存（PFS）的重要预测指标。结论：在使用常规R进行现代治疗的情况下，将患者分为好，中和差FLIPI风险组可预测OS和PFS的不同结局。 FLIPI在R时代仍然是重要的预后指标，应在临床实践中使用以支持有关预后的讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号